These findings contribute to our understanding of YY1‐mediated tumor immune regulation and present a potential therapeutic target for enhancing the efficacy of ICIs in HCC by targeting the glycosylation modifications of PD‐L1. This evidence concerns the gene YY1 and neoplasm.